Apple Tree Partners Ii Lp Sells 107,904 Shares of Aileron Therapeutics (ALRN) Stock

Aileron Therapeutics (NASDAQ:ALRN) major shareholder Apple Tree Partners Ii Lp sold 107,904 shares of the firm’s stock in a transaction that occurred on Thursday, April 19th. The shares were sold at an average price of $6.31, for a total transaction of $680,874.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ ALRN traded down $0.79 during midday trading on Thursday, reaching $6.01. 263,411 shares of the stock were exchanged, compared to its average volume of 31,640. The stock has a market cap of $102.99 and a price-to-earnings ratio of -3.40. Aileron Therapeutics has a 12 month low of $5.82 and a 12 month high of $15.48.

How to Become a New Pot Stock Millionaire

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Monday, April 2nd. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). analysts forecast that Aileron Therapeutics will post -2.06 EPS for the current fiscal year.

Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aileron Therapeutics currently has an average rating of “Buy” and an average price target of $19.33.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System bought a new position in shares of Aileron Therapeutics during the third quarter worth $110,000. Vanguard Group Inc. bought a new position in shares of Aileron Therapeutics during the second quarter worth $111,000. Bank of New York Mellon Corp bought a new position in shares of Aileron Therapeutics during the third quarter worth $135,000. Schwab Charles Investment Management Inc. bought a new position in shares of Aileron Therapeutics during the third quarter worth $165,000. Finally, Endurant Capital Management LP boosted its position in shares of Aileron Therapeutics by 24.0% during the fourth quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares in the last quarter. 7.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Apple Tree Partners Ii Lp Sells 107,904 Shares of Aileron Therapeutics (ALRN) Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2018/04/19/apple-tree-partners-ii-lp-sells-107904-shares-of-aileron-therapeutics-alrn-stock.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply